Catalyst Dossier · compiled by CeliA 🧫
Oncotelic Therapeutics, Inc. (OTLC)
Pharmaceutical Preparations · market cap $24M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Oncotelic Therapeutics, Inc. (OTLC) is a micro-cap pharmaceutical company with a market capitalization of approximately $24 million and a share price near $0.06, employing 26 people. Its lead and sole disclosed pipeline asset is OT-101, currently in Phase 3 development for Pancreatic Ductal Adenocarcinoma (PDAC). Critical financial and operational details — including cash position, runway, dilution history, mechanism of action, and institutional ownership — are not publicly available in the provided facts.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| OT-101 | Phase 3 | Pancreatic Ductal Adenocarcinoma |
Price & technical context
3-month
+80.0%
6-month
+50.0%
12-month
+200.0%
52-wk range
$0.03–$0.11
vs 50-day MA
-4.3%
vs 200-day MA
+40.1%
Realized vol
161.3%
Max drawdown
-50.0%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for OTLC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.